This bill would reauthorize an existing program which allows drug companies to receive a Priority Review Voucher (PRV) in order to have an expedited approval process for a treatment that would benefit pediatric rare disease patients. This is important to our community because we want the companies working on new treatments to have every tool available to get those treatments approved as quickly as possible for our community.
This legislation has broad bi-partisan support, but did not make it through the legislative process in 2024, expiring on December 20, 2024, despite a five-year reauthorization passing the House with bipartisan support.
On February 12, 2025, the Give Kids a Chance Act, H.R. 1262, was reintroduced by Representatives McCaul (TX) and Dingell (MI). The Give Kids a Chance Act would accelerate pediatric cancer treatments and expand access to life-saving therapies for children battling rare diseases as well as reauthorize the Rare Pediatric Review program. The Creating Hope Act of 2012 established the PRV Program to help expedite the development and promotion of drugs for diseases that disproportionately affect children. Since then, the PRV Program has incentivized the development of 58 new treatment options.
